Search results | pediatric

Reports

Pediatrics Partnering Terms and Agreements

The Pediatrics Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the pediatric partnering deals and agreements entered into by the worlds leading healthcare companies.

Insights

Arbor Pharma looking for an acquisition and merger partner

Arbor Pharmaceuticals LLC is allegedly exploring a potential acquisition and merger partner that could bring in more than $1 billion, according to people who are close to the situation.

Orphan diseases partnering: A lucrative step for drug makers

By Shamini Thiagarajan Increased collaborations, big pharma involvements, venture capital investments, and medical/technological breakthroughs are together changing the landscape of research and development in orphan diseases.

Pharma and biotech clinical stage partnering – recent trends 2009 to 2014

Partnering trends for the top pharma and biotech companies reviewed with over 2,000 deals analyzed – including summary biopharma deal financials

Abbott Laboratories

Abbott Laboratories is a top pharmaceutical company based in Illinois, USA

Dendreon: Company profile

Dendreon, a top big biotech company, is reviewed in terms of partnering, licensing and M&A interests and activity over recent years

Partnering with Merck & Co: Combining our strengths, sharing our successes

Merck & Co is a top pharma company active in partnering, licensing and M&A in pharmaceuticals, consumer health and animal health

Abbott Laboratories: Company profile

Abbott Laboratories, a top pharmaceutical company, is reviewed in terms of partnering, licensing and M&A interests and activity over recent years

Pharma partnering with Abbott: Transforming business through partnerships

Abbott Laboratories is a top pharma company active in pharma partnering, licensing and M&A in pharmaceuticals, diagnostics, devices and nutrition

Lupin eyes US market for M&A’s of up to $500 million

Lupin Ltd.is looking to aggressively grow its business in the U.S. and is scouting for M&A of pharmaceutical brands and manufacturers, and seeking regulatory approval to sell a wider range of niche generic drugs.

Aptalis Pharmaceutical Technologies: New formulations drive value

Written and published by partneringNEWS. By controlling the taste, bioavailability or timed release of drugs, Aptalis Pharmaceutical Technologies can help drug developers recoup the USD 30 billion lost to the industry each year because of patients not refilling—or never filling—their prescriptions. Controlling these factors also may improve compliance, lower dosage amounts, reduce side effects and more »

Events

Sorry, your search returned no results.


Deals

MAP Pharmaceuticals announces termination of AstraZeneca pediatric asthma collaboration

The termination was received on July 8, 2009, effective immediately. All rights licensed to AstraZeneca in the agreement now revert to the company.

Pfizer and Opko Health in growth hormone disorder pact

OPKO Health and Pfizer have entered into a worldwide agreement for the development and commercialization of OPKO’s long-acting hGH-CTP for the treatment of growth hormone deficiency

Xeltis secures series B financing for $34 million

Xeltis has raised EURO 27 million (USD 34 million/CHF 32 million) in an oversubscribed Series B financing

FSC Therapeutics signs a pharma deal with Eisai

FSC Therapeutics has entered into a transaction with Eisai Inc. to acquire exclusive U.S. marketing rights for AcipHex Sprinkle (rabeprazole sodium).

Janssen and ViiV Healthcare announce a HIV pharma deal

Janssen R&D and ViiV Healthcare have announced a pharma deal to combine both its HIV drug  therapies.

Big Pharma, Astellas collaborates with Starlight Childeren’s foundation

Big pharma, Astellas is again partnering with Starlight Children’s Foundation (“Starlight”), a leading global charity that partners with experts to improve the life and health of kids and families around the world through a unique blend of family-centered services from hospital to home.

Lumen gets $45 million in series B financing

Lumena Pharmaceuticals has secured $45 million in Series B financing.

GSK biopharma partners for raxibacumab with BARDA

GlaxoSmithKline , a big pharma company, announced a new four year contract with the Biomedical Advanced Research and Development Authority (BARDA), part of the US Department of Health and Human Services , for the provision of its inhalation anthrax treatment, raxibacumab, forming biopharma partners

Kyowa Hakko Kirin pharma deals Ultragenyx for KRN23 license

Ultragenyx Pharmaceutical has entered into pharma deals with Kyowa Hakko Kirin, to develop and commercialize KRN23.

Pfizer signs pharmaceutical deals for Prevenar 13 conjugate vaccine

Pfizer,a big pharma company, signs pharmaceutical deals to provide additional doses of Prevenar 13 (Pneumococcal Polysaccharide Conjugate Vaccine [13-valent, adsorbed]), the company’s 13-valent pneumococcal conjugate vaccine, for use in infants and young children to help protect against pneumococcal disease1 in the world’s poorest countries under the terms of the Advance Market Commitment.